8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2013 (June 18, 2013)

MYLAN INC.

(Exact Name of Registrant as Specified in Charter)

Pennsylvania	1-9114	25-1211621
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

1500 Corporate Drive Canonsburg, PA	15,317
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: (724) 514-1800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Item 8.01. Other Events.

On June 18, 2013, Mylan Inc. (the "Company") issued a press release announcing its intention to privately place $500 million aggregate principal amount of 1.80% senior notes due 2016 and $650 million aggregate principal amount of 2.60% senior notes due 2018. The offering is expected to close on June 25, 2013, subject to customary closing conditions. A copy of the press release is attached hereto as Exhibit 99.1.

The Company also announced that it is in the process of refinancing its revolving credit facility to increase its size from $1.25 billion to $1.5 billion and to remove the security and guarantee provisions that are features of the Company's existing revolving credit facility.

In addition, the Company announced that it intends to redeem all of its outstanding 7.625% Senior Notes due 2017 (CUSIP Nos. 628530AK3, U62472AB8 and 628530AM9) (the "Notes") pursuant to their terms on July 18, 2013 (the "Redemption Date"). (The attached press release incorrectly indicates that the Redemption Date is July 17, 2013.) The redemption price for each Note redeemed at the Redemption Date will be equal to 100% of the principal amount of such Note, plus the excess of (a) the present value at the Redemption Date of (i) 103.813% of the principal amount of such Note plus (ii) all scheduled interest payments due on such Note through July 15, 2014 (excluding accrued but unpaid interest to the Redemption Date), computed using a discount rate equal to the Treasury Rate (as such term is defined in the indenture governing the Notes) as of the Redemption Date plus 50 basis points; over (b) the principal amount of such Note as of the Redemption Date, plus accrued and unpaid interest on the Note, if any, to the Redemption Date. Redemption of the Notes is expected to occur through the facilities of The Depository Trust Company. The Company anticipates that it will take a pre-tax charge of approximately $65 million upon the redemption of the Notes, which it expects to be partially offset by reduced interest expense through the first call date of such notes.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Pricing Press Release of Mylan Inc., dated June 18, 2013.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MYLAN INC.
Date: June 18, 2013	By:	/s/ John D. Sheehan
		John D. Sheehan
		Executive Vice President & Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Pricing Press Release of Mylan Inc., dated June 18, 2013.

EX-99.1

Exhibit 99.1

Mylan Announces Pricing of Senior Notes

PITTSBURGH-June 18, 2013-Mylan Inc. (Nasdaq: MYL) today announced the pricing of a private placement of $500 million aggregate principal amount of 1.80% Senior Notes due 2016 at an issue price of 99.925% and $650 million aggregate principal amount of 2.60% Senior Notes due 2018 at an issue price of 99.791%. Mylan intends to use the net proceeds from the offering to repay term loans borrowed under its credit facility. Subject to customary closing conditions, the sale of the notes is expected to close on or about June 25, 2013.

The notes will be sold only to qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act of 1933, and outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act. The proposed issuance of the notes will not be registered under the Securities Act, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities mentioned in this press release in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Mylan also announced that it is in the process of refinancing its revolving credit facility to increase its size from $1.25 billion to $1.5 billion and to remove the security and guarantee provisions that are features of its existing revolving credit facility. In addition, Mylan announced that it intends to redeem all of its outstanding 7.625% Senior Notes due 2017 (CUSIP Nos. 628530AK3, U62472AB8 and 628530AM9) pursuant to their terms on July 17, 2013.

This press release contains forward-looking statements relating to the consummation of the offering described above, the anticipated use of proceeds therefrom, the proposed refinancing of Mylan's revolving credit facility and the redemption of a series of the Company's senior notes. Consummation of the offering is subject to a number of conditions, some of which are beyond Mylan's control. Therefore, no assurance can be given that the offering will be consummated on the terms described or at all, or that the proceeds will be able to be deployed as indicated. Neither can any assurance be provided that Mylan's existing revolving credit facility will be refinanced on the terms described or at all or that such redemption will be consummated within the timeframe indicated or at all.

1500 Corporate Drive, Canonsburg, PA 15317P: 724.514.1800F: 724.514.1870Mylan.com

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside.

###